Exact Mass: 483.2961

Exact Mass Matches: 483.2961

Found 29 metabolites which its exact mass value is equals to given mass value 483.2961, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Taurolithocholate

2-[(4R)-4-[(1S,2S,5R,7R,10R,11S,14R,15R)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pentanamido]ethane-1-sulfonic acid

C26H45NO5S (483.3018)


Lithocholyltaurine is a bile salt formed in the liver from lithocholic acid conjugation with taurine, usually as the sodium salt. It solubilizes fats for absorption and is itself absorbed. Lithocholic acid, a hydrophobic secondary bile acid, is well known to cause intrahepatic cholestasis. There have been extensive studies on the mechanisms of lithocholate-induced cholestasis in animals. Lithocholate diminishes both the bile acid-dependent and independent bile flow. In humans, elevated levels of lithocholic acid are found in patients with chronic cholestatic liver disease. Lithocholyltaurine impairs both the bile canalicular contractions and the canalicular bile secretion, possibly by acting directly on the canalicular membranes in lithocholyltaurine-induced cholestasis. Lithocholyltaurine induce acute cholestasis-associated with retrieval of the bile salt export pump. The bile salt export pump (BSEP) of hepatocyte secretes conjugated bile salts across the canalicular membrane in an ATP-dependent manner. Hepatic retention of bile acids may lead to liver injury by hepatocyte apoptosis and eventually deterioration of cholestatic liver diseases. One mechanism of induced apoptosis by lithocholyltaurine is the induction of transcriptional activity of AP-1 (activation protein-1). (PMID: 16981261, 15763547, 16332456, 18164257) [HMDB] Lithocholyltaurine is a bile salt formed in the liver from lithocholic acid conjugation with taurine, usually as the sodium salt. It solubilizes fats for absorption and is itself absorbed. Lithocholic acid, a hydrophobic secondary bile acid, is well known to cause intrahepatic cholestasis. There have been extensive studies on the mechanisms of lithocholate-induced cholestasis in animals. Lithocholate diminishes both the bile acid-dependent and independent bile flow. In humans, elevated levels of lithocholic acid are found in patients with chronic cholestatic liver disease. Lithocholyltaurine impairs both the bile canalicular contractions and the canalicular bile secretion, possibly by acting directly on the canalicular membranes in lithocholyltaurine-induced cholestasis. Lithocholyltaurine induce acute cholestasis-associated with retrieval of the bile salt export pump. The bile salt export pump (BSEP) of hepatocyte secretes conjugated bile salts across the canalicular membrane in an ATP-dependent manner. Hepatic retention of bile acids may lead to liver injury by hepatocyte apoptosis and eventually deterioration of cholestatic liver diseases. One mechanism of induced apoptosis by lithocholyltaurine is the induction of transcriptional activity of AP-1 (activation protein-1). (PMID: 16981261, 15763547, 16332456, 18164257). D005765 - Gastrointestinal Agents > D002756 - Cholagogues and Choleretics D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids D013501 - Surface-Active Agents > D003902 - Detergents CONFIDENCE standard compound; INTERNAL_ID 61

   

Hydroxybuprenorphine

Hydroxybuprenorphine

C29H41NO5 (483.2985)


Hydroxybuprenorphine is a metabolite of Buprenorphine. Buprenorphine is a semi-synthetic opioid that is used to treat opioid addiction in higher dosages (>2 mg), to control moderate acute pain in non-opioid-tolerant individuals in lower dosages (~200 µg), and to control moderate chronic pain in dosages ranging from 20–70 µg/hour. It is available in a variety of formulations: Subutex, Suboxone (buprenorphine HCl and naloxone HCl; typically used for opioid addiction), Temgesic (sublingual tablets for moderate to severe pain), Buprenex (solutions for injection often used for acute pain in primary-care settings), Norspan and Butrans (transdermal preparations used for chronic pain). (Wikipedia)

   
   

Taurolithocholic acid

Taurolithocholic acid

C26H45NO5S (483.3018)


D005765 - Gastrointestinal Agents > D002756 - Cholagogues and Choleretics D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids D013501 - Surface-Active Agents > D003902 - Detergents The bile acid taurine conjugate of lithocholic acid. KEIO_ID T072

   

Tauro 3a-OH-5b-cholanic acid

Tauro 3a-OH-5b-cholanic acid

C26H45NO5S (483.3018)


BA-134-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-134-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-134-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-134-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.

   

2-((4R)-4-((5S,9S,10S,12R,13R,14S,17R)-12-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid

"2-((4R)-4-((5S,9S,10S,12R,13R,14S,17R)-12-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid"

C26H45NO5S (483.3018)


   

2-((4R)-4-((3R,5R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid

"2-((4R)-4-((3R,5R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid"

C26H45NO5S (483.3018)


   

2-((4R)-4-((5S,9S,10S,12S,13R,14S,17R)-12-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid

"2-((4R)-4-((5S,9S,10S,12S,13R,14S,17R)-12-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid"

C26H45NO5S (483.3018)


   

Lithocholyltaurine

Lithocholyltaurine

C26H45NO5S (483.3018)


D005765 - Gastrointestinal Agents > D002756 - Cholagogues and Choleretics D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids D013501 - Surface-Active Agents > D003902 - Detergents

   

PS(O-16:0/0:0)

1-hexadecyl-glycero-3-phosphoserine

C22H46NO8P (483.2961)


   

LPS O-16:0

1-hexadecyl-glycero-3-phosphoserine

C22H46NO8P (483.2961)


   

pseudomonate C

pseudomonate C

C26H43O8- (483.2958)


   

(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-8-(4-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-8-(4-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

C28H38FN3O3 (483.2897)


   

(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-8-(4-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-8-(4-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

C28H38FN3O3 (483.2897)


   

2-((4R)-4-((5S,9S,10S,12S,13R,14S,17R)-12-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid

2-((4R)-4-((5S,9S,10S,12S,13R,14S,17R)-12-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid

C26H45NO5S (483.3018)


   

2-[[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]amino]-3-hydroxydecane-1-sulfonic acid

2-[[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]amino]-3-hydroxydecane-1-sulfonic acid

C26H45NO5S (483.3018)


   

(E)-2-[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]amino]-3-hydroxydec-4-ene-1-sulfonic acid

(E)-2-[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]amino]-3-hydroxydec-4-ene-1-sulfonic acid

C26H45NO5S (483.3018)


   

2-[4-[(3R,5R,8R,9S,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]ethanesulfonic acid

2-[4-[(3R,5R,8R,9S,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]ethanesulfonic acid

C26H45NO5S (483.3018)


   

2-[[(4R)-4-[(5S,8R,9S,10S,12R,13R,14S,17R)-12-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonic acid

2-[[(4R)-4-[(5S,8R,9S,10S,12R,13R,14S,17R)-12-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonic acid

C26H45NO5S (483.3018)


   

1-hexadecyl-glycero-3-phosphoserine

1-hexadecyl-glycero-3-phosphoserine

C22H46NO8P (483.2961)


   

NA-DOPA 20:4(5Z,8Z,11Z,14Z)

NA-DOPA 20:4(5Z,8Z,11Z,14Z)

C29H41NO5 (483.2985)


   

ST 27:5;O3;Gly

ST 27:5;O3;Gly

C29H41NO5 (483.2985)


   
   

9,18,20,26-tetramethyl-1-azacyclohexacosa-1,3,5,7,15,17,19,21,23-nonaene-2,10,11,12,14-pentol

9,18,20,26-tetramethyl-1-azacyclohexacosa-1,3,5,7,15,17,19,21,23-nonaene-2,10,11,12,14-pentol

C29H41NO5 (483.2985)


   

methyl (3s,3'r,3'as,6's,6as,6bs,7'ar,9r,11as,11br)-3-hydroxy-3',6',10,11b-tetramethyl-11-oxo-1,2,3,3',3'a,4,5',6,6',6a,6b,7,7',7'a,8,11a-hexadecahydrospiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridine]-4'-carboxylate

methyl (3s,3'r,3'as,6's,6as,6bs,7'ar,9r,11as,11br)-3-hydroxy-3',6',10,11b-tetramethyl-11-oxo-1,2,3,3',3'a,4,5',6,6',6a,6b,7,7',7'a,8,11a-hexadecahydrospiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridine]-4'-carboxylate

C29H41NO5 (483.2985)


   

(9s,10r,11r,12s,14r,15e,26s)-9,19,21,26-tetramethyl-1-azacyclohexacosa-1,3,5,7,15,17,19,21,23-nonaene-2,10,11,12,14-pentol

(9s,10r,11r,12s,14r,15e,26s)-9,19,21,26-tetramethyl-1-azacyclohexacosa-1,3,5,7,15,17,19,21,23-nonaene-2,10,11,12,14-pentol

C29H41NO5 (483.2985)


   

(9s,10r,11r,12s,14r,15z,26s)-9,19,21,26-tetramethyl-1-azacyclohexacosa-1,3,5,7,15,17,19,21,23-nonaene-2,10,11,12,14-pentol

(9s,10r,11r,12s,14r,15z,26s)-9,19,21,26-tetramethyl-1-azacyclohexacosa-1,3,5,7,15,17,19,21,23-nonaene-2,10,11,12,14-pentol

C29H41NO5 (483.2985)


   

(3e,5e,7e,15e,17e,19e,21e,23z)-9,18,20,26-tetramethyl-1-azacyclohexacosa-1,3,5,7,15,17,19,21,23-nonaene-2,10,11,12,14-pentol

(3e,5e,7e,15e,17e,19e,21e,23z)-9,18,20,26-tetramethyl-1-azacyclohexacosa-1,3,5,7,15,17,19,21,23-nonaene-2,10,11,12,14-pentol

C29H41NO5 (483.2985)


   

methyl (3s,3's,3'as,6's,6as,6br,7'as,9r,11ar,11br)-3-hydroxy-3',6',10,11b-tetramethyl-11-oxo-1,2,3,3',3'a,4,5',6,6',6a,6b,7,7',7'a,8,11a-hexadecahydrospiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridine]-4'-carboxylate

methyl (3s,3's,3'as,6's,6as,6br,7'as,9r,11ar,11br)-3-hydroxy-3',6',10,11b-tetramethyl-11-oxo-1,2,3,3',3'a,4,5',6,6',6a,6b,7,7',7'a,8,11a-hexadecahydrospiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridine]-4'-carboxylate

C29H41NO5 (483.2985)